华仁药业：子公司盐酸异丙肾上腺素原料药获上市批准

Core Viewpoint - Hainan Pharmaceutical's subsidiary, Anhui Hengxing Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of "Isoproterenol Hydrochloride" [1] Company Summary - The approval of Isoproterenol Hydrochloride, a non-selective β-adrenergic agonist, will enhance the company's active pharmaceutical ingredient (API) product line [1] - This product is primarily used for treating cardiogenic or infectious shock, complete atrioventricular block, cardiac arrest, and acute bronchial asthma attacks [1] - The addition of this product is expected to improve the company's market competitiveness [1]